Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 10, 2023 11:00 ET | Source: Jasper Therapeutics

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

REDWOOD CITY, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy...
November 30, 2023 08:00 ET | Source: Jasper Therapeutics

Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

REDWOOD CITY, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
November 08, 2023 16:30 ET | Source: Jasper Therapeutics

Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences

REDWOOD CITY, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy...
November 02, 2023 09:00 ET | Source: Jasper Therapeutics

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy...
November 01, 2023 08:00 ET | Source: Jasper Therapeutics

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy...
October 09, 2023 08:30 ET | Source: Jasper Therapeutics

Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023

REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy...
October 09, 2023 08:00 ET | Source: Jasper Therapeutics

Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria

First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical Study in Chronic Inducible Urticaria Planned to Commence in Early 2024 REDWOOD CITY, Calif., Oct. 09,...
September 25, 2023 08:00 ET | Source: Jasper Therapeutics

Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer

REDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody...
September 21, 2023 08:00 ET | Source: Jasper Therapeutics

Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium

All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recoveryBriquilimab was well tolerated without any complicationsStudy expansion to Phase...
September 15, 2023 08:00 ET | Source: Jasper Therapeutics

Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference

REDWOOD CITY, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...